{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T01:22:33Z","timestamp":1783646553528,"version":"3.55.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T00:00:00Z","timestamp":1646006400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Hepatocellular carcinoma (HCC) has high incidence and mortality worldwide. Local ablation using radiofrequency ablation (RFA) or microwave ablation (MWA) is potentially curative for early-stage HCC with outcomes comparable to surgical resection. We explored the influence of demographic, clinical, and laboratory factors on outcomes of HCC patients receiving ablation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This retrospective cohort study included 221 HCC patients receiving local ablation at Mayo Clinic between January 2000 and October 2018, comprising 140 RFA and 81 MWA. Prognostic factors determining overall survival (OS) and disease-free survival (DFS) were identified using multivariate analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>There was no clinically significant difference in OS or DFS between RFA and MWA. In multivariate analysis of OS, pre-ablation lymphocyte-monocyte ratio [Hazard ratio (HR) 0.7, 95% confidence interval (CI) 0.58\u20130.84, <jats:italic>P<\/jats:italic>\u2009=\u20090.0001], MELD score [HR 1.12, 95%CI 1.068\u20131.17, <jats:italic>P<\/jats:italic>\u2009&lt;\u2009\u00a00.0001], tumor number [HR 1.23, 95%CI 1.041\u20131.46, <jats:italic>P<\/jats:italic>\u2009=\u20090.015] and tumor size [HR 1.18, 95%CI 1.015\u20131.37, <jats:italic>P<\/jats:italic>\u2009=\u20090.031] were clinically-significant prognostic factors. Among HCC patients with chronic hepatitis C (HCV) infection, positive HCV PCR at HCC diagnosis was associated with 1.4-fold higher hazard\u00a0of death, with 5-year survival of 32.8% vs 53.6% in HCV PCR-negative patients. Regarding DFS, pre-ablation lymphocyte-monocyte ratio [HR 0.77, 95%CI 0.66\u20130.9, <jats:italic>P<\/jats:italic>\u2009=\u20090.001], MELD score [HR 1.06, 95%CI 1.022\u20131.11, <jats:italic>P<\/jats:italic>\u2009=\u20090.002], Log<jats:sup>2<\/jats:sup> AFP [HR 1.11, 95%CI 1.033\u20131.2, <jats:italic>P<\/jats:italic>\u2009=\u20090.005], tumor number [HR 1.29, 95%CI 1.078\u20131.53, <jats:italic>P<\/jats:italic>\u2009=\u20090.005] and tumor size [HR 1.25, 95%CI 1.043\u20131.51 <jats:italic>P<\/jats:italic>\u2009=\u20090.016] were independently prognostic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Pre-ablation systemic inflammation represented by lymphocyte-monocyte ratio is significantly associated with OS and DFS in HCC patients treated with local ablation. HCV viremia is associated with poor OS. Tumor biology represented by tumor number and size are strongly prognostic for OS and DFS while AFP is significantly associated with DFS only.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-021-09121-8","type":"journal-article","created":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T16:03:16Z","timestamp":1646064196000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prognostic utility of systemic inflammatory markers and chronic hepatitis C virus infection status in hepatocellular carcinoma patients treated with local ablation"],"prefix":"10.1186","volume":"22","author":[{"given":"Mohamed Abdulwahab Mohamed","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William Scott","family":"Harmsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khairy Hammam","family":"Morsy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghada Moustapha Kamal","family":"Galal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry M.","family":"Therneau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lewis Rowland","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,28]]},"reference":[{"issue":"6","key":"9121_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424. https:\/\/doi.org\/10.3322\/caac.21492 PMID: 30207593.","journal-title":"CA Cancer J Clin"},{"key":"9121_CR2","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.jhep.2011.12.001","volume":"56","author":"European Association for the Study of the Liver; European Organization For Research And Treatment Of Cancer","year":"2012","unstructured":"European Association for the Study of the Liver; European Organization For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908\u201343 [PMID: 22424438. https:\/\/doi.org\/10.1016\/j.jhep.2011.12.001.","journal-title":"J Hepatol"},{"issue":"11","key":"9121_CR3","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1097\/01.RVI.90000172121.82299.38","volume":"16","author":"CM Pacella","year":"2005","unstructured":"Pacella CM, Bizzarri G, Francica G, Bianchini A, De Nuntis S, Pacella S, et al. Percutaneous laser ablation in the treatment of hepatocellular carcinoma with small tumors: analysis of factors affecting the achievement of tumor necrosis. J Vasc IntervRadiol. 2005;16(11):1447\u201357 [PMID: 16319150].","journal-title":"J Vasc IntervRadiol"},{"issue":"6","key":"9121_CR4","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1080\/00365520701885481","volume":"43","author":"F Brunello","year":"2008","unstructured":"Brunello F, Veltri A, Carucci P, Pagano E, Ciccone G, Moretto P, et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol. 2008;43(6):727\u201335. [PMID: 18569991. https:\/\/doi.org\/10.1080\/00365520701885481.","journal-title":"Scand J Gastroenterol"},{"issue":"2","key":"9121_CR5","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1148\/radiol.2232010775","volume":"223","author":"T Shibata","year":"2002","unstructured":"Shibata T, Iimuro Y, Yamamoto Y, Maetani Y, Ametani F, Itoh K, et al. Small hepatocellular carcinoma: comparison of radio-frequency ablation and percutaneous microwave coagulation therapy. Radiology. 2002;223(2):331\u20137 [PMID: 11997534].","journal-title":"Radiology."},{"issue":"11","key":"9121_CR6","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1046\/j.1365-2168.2002.02292.x","volume":"89","author":"AJ Sheen","year":"2002","unstructured":"Sheen AJ, Poston GJ, Sherlock DJ. Cryotherapeutic ablation of liver tumours. Br J Surg. 2002;89(11):1396\u2013401 PMID: 12390380.","journal-title":"Br J Surg"},{"issue":"5","key":"9121_CR7","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jvir.2010.12.014","volume":"22","author":"KR Thomson","year":"2011","unstructured":"Thomson KR, Cheung W, Ellis SJ, Federman D, Kavnoudias H, Loader-Oliver D, et al. Investigation of the safety of irreversible electroporation in humans. J Vasc Interv Radiol. 2011;22(5):611\u201321. https:\/\/doi.org\/10.1016\/j.jvir.2010.12.014 PMID: 21439847.","journal-title":"J Vasc Interv Radiol"},{"issue":"12","key":"9121_CR8","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.ultrasmedbio.2011.08.011","volume":"37","author":"G Xu","year":"2011","unstructured":"Xu G, Luo G, He L, Li J, Shan H, Zhang R, et al. Follow-up of high-intensity focused ultrasound treatment for patients with hepatocellular carcinoma. Ultrasound Med Biol. 2011;37(12):1993\u20139. https:\/\/doi.org\/10.1016\/j.ultrasmedbio.2011.08.011 PMID: PMID: 22036638.","journal-title":"Ultrasound Med Biol"},{"key":"9121_CR9","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/j.1365-2036.2010.04370.x","volume":"32","author":"W Alazawi","year":"2010","unstructured":"Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32:344\u201355.","journal-title":"Aliment Pharmacol Ther"},{"key":"9121_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jhep.2017.01.033","volume":"67","author":"G Cabibbo","year":"2017","unstructured":"Cabibbo G, Petta S, Barbara M, Attardo S, Bucci L, et al. Hepatic decompensation is the major driver of death in hcv-infected cirrhotic patients with successfully treated early hepatocellular carcinoma. J Hepatol. 2017;67:65\u201371.","journal-title":"J Hepatol"},{"issue":"4","key":"9121_CR11","doi-asserted-by":"publisher","first-page":"185","DOI":"10.23736\/S0031-0808.18.03472-9","volume":"60","author":"M Ru\u017ei\u0107","year":"2018","unstructured":"Ru\u017ei\u0107 M, Pellicano R, Fabri M, Luzza F, Boccuto L, Brki\u0107 S, et al. Hepatitis C virus-induced hepatocellular carcinoma: a narrative review. Panminerva Med. 2018;60(4):185\u201391. https:\/\/doi.org\/10.23736\/S0031-0808.18.03472-9 Epub 2018 Jun 1. PMID: 29856183.","journal-title":"Panminerva Med"},{"issue":"18","key":"9121_CR12","doi-asserted-by":"publisher","first-page":"26916","DOI":"10.18632\/oncotarget.8309","volume":"7","author":"R Berardi","year":"2016","unstructured":"Berardi R, Rinaldi S, Santoni M, Newsom-Davis T, Tiberi M, Morgese F, et al. Prognostic models to predict survival in patients with advanced non-small cell lung cancer treated with first-line chemo- or targeted therapy. Oncotarget. 2016;7(18):26916\u201324. https:\/\/doi.org\/10.18632\/oncotarget.8309 PMID: 27029035.","journal-title":"Oncotarget"},{"key":"9121_CR13","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.amjsurg.2009.08.041","volume":"200","author":"I Bhatti","year":"2010","unstructured":"Bhatti I, Peacock O, Lloyd G, Larvin M, Hall RI. Preoperative hematologic markers as independent predictors of prognosis in resected pancreatic ductal adenocarcinoma: neutrophil-lymphocyte versus platelet-lymphocyte ratio. Am J Surg. 2010;200:197\u2013203. https:\/\/doi.org\/10.1016\/j.amjsurg.2009.08.041 PMID: 20122680.","journal-title":"Am J Surg"},{"key":"9121_CR14","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1023\/B:AGEN.0000029415.62384.ba","volume":"6","author":"YH Kusumanto","year":"2003","unstructured":"Kusumanto YH, Dam WA, Hospers GA, Meijer C, Mulder NH. Platelets and granulocytes, in particular the neutrophils, form important compartments for circulating vascular endothelial growth factor. Angiogenesis. 2003;6:283\u20137. https:\/\/doi.org\/10.1023\/B:AGEN.0000029415.62384.ba PMID: 15166496.","journal-title":"Angiogenesis"},{"key":"9121_CR15","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/jso.10188","volume":"82","author":"K Okano","year":"2003","unstructured":"Okano K, Maeba T, Moroguchi A, Ishimura K, Karasawa Y, Izuishi K, et al. Lymphocytic infiltration surrounding liver metastases from colorectal cancer. J Surg Oncol. 2003;82:28\u201333. https:\/\/doi.org\/10.1002\/jso.10188 PMID: 12501166.","journal-title":"J Surg Oncol"},{"issue":"12","key":"9121_CR16","doi-asserted-by":"publisher","first-page":"7165","DOI":"10.4049\/jimmunol.0902583","volume":"185","author":"S Augier","year":"2010","unstructured":"Augier S, Ciucci T, Luci C, Carle GF, Blin-Wakkach C, Wakkach A. Inflammatory blood monocytes contribute to tumor development and represent a privileged target to improve host Immunosurveillance. J Immunol. 2010;185(12):7165\u201373. https:\/\/doi.org\/10.4049\/jimmunol.0902583 PMID: 21078911.","journal-title":"J Immunol"},{"key":"9121_CR17","doi-asserted-by":"publisher","first-page":"1640","DOI":"10.1002\/ijc.24556","volume":"125","author":"J Zhou","year":"2009","unstructured":"Zhou J, Ding T, Pan W, Zhu LY, Li L, Zheng L. Increased intratumoral regulatory T cells are related to intratumoral macrophages and poor prognosis in hepatocellular carcinoma patients. Int J Cancer. 2009;125:1640\u20138. https:\/\/doi.org\/10.1002\/ijc.24556 PMID: 19569243.","journal-title":"Int J Cancer"},{"key":"9121_CR18","doi-asserted-by":"publisher","first-page":"46601","DOI":"10.1038\/srep46601","volume":"7","author":"W Song","year":"2017","unstructured":"Song W, Tian C, Wang K, Zhang R, Zou S. The pretreatment lymphocyte to monocyte ratio predicts clinical outcome for patients with hepatocellular carcinoma: a meta-analysis. Sci Rep. 2017;7:46601. https:\/\/doi.org\/10.1038\/srep46601 PMID: 28417972.","journal-title":"Sci Rep"},{"issue":"11","key":"9121_CR19","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1002\/lt.25204","volume":"24","author":"Y Mano","year":"2018","unstructured":"Mano Y, Yoshizumi T, Yugawa K, Ohira M, Motomura T, Toshima T, et al. Lymphocyte-to-monocyte ratio is a predictor of survival after liver transplantation for hepatocellular carcinoma. Liver Transpl. 2018;24(11):1603\u201311. https:\/\/doi.org\/10.1002\/lt.25204 PMID: 29893464.","journal-title":"Liver Transpl"},{"issue":"5","key":"9121_CR20","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s12072-020-10076-4","volume":"14","author":"Y Ha","year":"2020","unstructured":"Ha Y, Mohamed Ali MA, Petersen MM, Harmsen WS, Therneau TM, Lee HC, et al. Lymphocyte to monocyte ratio-based nomogram for predicting outcomes of hepatocellular carcinoma treated with sorafenib. Hepatol Int. 2020;14(5):776\u201387. https:\/\/doi.org\/10.1007\/s12072-020-10076-4 Epub 2020 Aug 1. PMID: 32740886.","journal-title":"Hepatol Int"},{"issue":"1","key":"9121_CR21","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1080\/02656736.2018.1562571","volume":"36","author":"W Tan","year":"2019","unstructured":"Tan W, Deng Q, Lin S, Wang Y, Xu G. Comparison of microwave ablation and radiofrequency ablation for hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperth. 2019;36(1):264\u201372. https:\/\/doi.org\/10.1080\/02656736.2018.1562571 PMID: 30676100.","journal-title":"Int J Hyperth"},{"issue":"7","key":"9121_CR22","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1001\/jama.1982.03320320040027","volume":"247","author":"HW Bruckner","year":"1982","unstructured":"Bruckner HW, Lavin PT, Plaxe SC, Storch JA, Livstone EM. Absolute granulocyte, lymphocyte, and monocyte counts. Useful determinants of prognosis for patients with metastatic cancer of the stomach. JAMA. 1982;247(7):1004\u20136 [PMID: 7035703].","journal-title":"JAMA."},{"issue":"2","key":"9121_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/mutage\/gep053","volume":"25","author":"N Gungor","year":"2010","unstructured":"Gungor N, Knaapen AM, Munnia A, Peluso M, Haenen GR, Chiu RK, et al. Genotoxic effects of neutrophils and hypochlorous acid. Mutagenesis. 2010;25(2):149\u201354. https:\/\/doi.org\/10.1093\/mutage\/gep053 PMID: 19892774.","journal-title":"Mutagenesis"},{"key":"9121_CR24","doi-asserted-by":"publisher","first-page":"5034","DOI":"10.4049\/jimmunol.172.8.5034","volume":"172","author":"P Scapini","year":"2004","unstructured":"Scapini P, Morini M, Tecchio C, Minghelli S, Di Carlo E, Tanghetti E, et al. CXCL1\/macrophage inflammatory protein- 2-induced angiogenesis in vivo is mediated by neutrophil derived vascular endothelial growth factor-A. J Immunol. 2004;172:5034\u201340 [PMID: 15067085].","journal-title":"J Immunol"},{"issue":"5","key":"9121_CR25","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/j.jhep.2010.08.041","volume":"54","author":"DM Kuang","year":"2011","unstructured":"Kuang DM, Zhao Q, Wu Y, Peng C, Wang J, Xu Z, et al. Peritumoral neutrophils link inflammatory response to disease progression by fostering angiogenesis in hepatocellular carcinoma. J Hepatol. 2011;54(5):948\u201355. https:\/\/doi.org\/10.1016\/j.jhep.2010.08.041 PMID: 21145847.","journal-title":"J Hepatol"},{"issue":"2","key":"9121_CR26","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1136\/gutjnl-2015-310814","volume":"66","author":"M Garnelo","year":"2017","unstructured":"Garnelo M, Tan A, Her Z, Yeong J, Lim CJ, Chen J, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma. Gut. 2017;66(2):342\u201351. https:\/\/doi.org\/10.1136\/gutjnl-2015-310814 PMID: 26669617.","journal-title":"Gut"},{"issue":"34","key":"9121_CR27","doi-asserted-by":"publisher","first-page":"35602","DOI":"10.18632\/oncotarget.5801","volume":"6","author":"C Sun","year":"2015","unstructured":"Sun C, Xu J, Song J, Liu C, Wang J, Weng C, et al. The predictive value of centre tumour CD8+ T cells in patients with hepatocellular carcinoma: comparison with Immunoscore. Oncotarget. 2015;6(34):35602\u201315. https:\/\/doi.org\/10.18632\/oncotarget.5801 PMID: 26415232.","journal-title":"Oncotarget"},{"issue":"6","key":"9121_CR28","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.1016\/S0002-9440(10)65436-3","volume":"154","author":"R Dolcetti","year":"1999","unstructured":"Dolcetti R, Viel A, Doglioni C, Russo A, Guidoboni M, Capozzi E, et al. High prevalence of activated intraepithelial cytotoxic T lymphocytes and increased neoplastic cell apoptosis in colorectal carcinomas with microsatellite instability. Am J Pathol. 1999;154(6):1805\u201313 [PMID: 10362805].","journal-title":"Am J Pathol"},{"issue":"4","key":"9121_CR29","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/nrc3245","volume":"12","author":"WH Fridman","year":"2012","unstructured":"Fridman WH, Pag\u00e8s F, Saut\u00e8s-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298\u2013306. https:\/\/doi.org\/10.1038\/nrc3245 PMID: 22419253.","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"9121_CR30","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.jhep.2012.06.022","volume":"57","author":"DJ Pinato","year":"2012","unstructured":"Pinato DJ, Stebbing J, Ishizuka M, Khan SA, Wasan HS, North BV, et al. A novel and validated prognostic index in hepatocellular carcinoma: the inflammation based index (IBI). J Hepatol. 2012;57(5):1013\u201320. https:\/\/doi.org\/10.1016\/j.jhep.2012.06.022 PMID: 22732513.","journal-title":"J Hepatol"},{"issue":"11","key":"9121_CR31","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.imbio.2013.06.003","volume":"218","author":"MR Galdiero","year":"2013","unstructured":"Galdiero MR, Bonavita E, Barajon I, Garlanda C, Mantovani A, Jaillon S. Tumor associated macrophages and neutrophils in cancer. Immunobiology. 2013;218(11):1402\u201310. https:\/\/doi.org\/10.1016\/j.imbio.2013.06.003 PMID: 23891329.","journal-title":"Immunobiology"},{"issue":"1","key":"9121_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s12929-019-0568-z","volume":"26","author":"Y Chen","year":"2019","unstructured":"Chen Y, Song Y, Du W, Gong L, Chang H, Zou Z. Tumor-associated macrophages: an accomplice in solid tumor progression. J Biomed Sci. 2019;26(1):78. https:\/\/doi.org\/10.1186\/s12929-019-0568-z Published 2019 Oct 20.","journal-title":"J Biomed Sci"},{"issue":"8","key":"9121_CR33","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1007\/s00268-008-9552-6","volume":"32","author":"D Gomez","year":"2008","unstructured":"Gomez D, Farid S, Malik HZ, Young AL, Toogood GJ, Lodge JP, et al. Preoperative neutrophilto-lymphocyte ratio as a prognostic predictor after curative resection for hepatocellular carcinoma. World J Surg. 2008;32(8):1757\u201362. https:\/\/doi.org\/10.1007\/s00268-008-9552-6 PMID: 18340479.","journal-title":"World J Surg"},{"issue":"1","key":"9121_CR34","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1097\/SLA.0b013e3181a77e59","volume":"250","author":"KJ Halazun","year":"2009","unstructured":"Halazun KJ, Hardy MA, Rana AA, Woodland DC 4th, Luyten EJ, Mahadev S, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg. 2009;250(1):141\u201351. https:\/\/doi.org\/10.1097\/SLA.0b013e3181a77e59 [PMID: 19561458].","journal-title":"Ann Surg"},{"issue":"3","key":"9121_CR35","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1111\/j.1440-1746.2011.06910.x","volume":"27","author":"TM Chen","year":"2012","unstructured":"Chen TM, Lin CC, Huang PT, Wen CF. Neutrophil-to-lymphocyte ratio associated with mortality in early hepatocellular carcinoma patients after radiofrequency ablation. J Gastroenterol Hepatol. 2012;27(3):553\u201361. https:\/\/doi.org\/10.1111\/j.1440-1746.2011.06910.x PMID: 21913982.","journal-title":"J Gastroenterol Hepatol"},{"issue":"7","key":"9121_CR36","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1111\/hepr.12417","volume":"45","author":"K Tajiri","year":"2015","unstructured":"Tajiri K, Kawai K, Minemura M, Yasumura S, Hosokawa A, Kawabe H, et al. Neutrophil\/ lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. Hepatol Res. 2015;45(7):755\u201363. https:\/\/doi.org\/10.1111\/hepr.12417 PMID: 25196816.","journal-title":"Hepatol Res"},{"issue":"11","key":"9121_CR37","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1007\/s12032-014-0264-5","volume":"31","author":"LG da Fonseca","year":"2014","unstructured":"da Fonseca LG, Barroso-Sousa R, Bento Ada S, Blanco BP, Valente GL, Pfiffer TE, et al. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib. Med Oncol. 2014;31(11):264. https:\/\/doi.org\/10.1007\/s12032-014-0264-5 PMID: 25273866.","journal-title":"Med Oncol"},{"issue":"1","key":"9121_CR38","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41598-018-20199-2","volume":"8","author":"YT Yang","year":"2018","unstructured":"Yang YT, Jiang JH, Yang HJ, Wu ZJ, Xiao ZM, Xiang BD. The lymphocyte-to-monocyte ratio is a superior predictor of overall survival compared to established biomarkers in HCC patients undergoing liver resection. Sci Rep. 2018;8(1):2535. https:\/\/doi.org\/10.1038\/s41598-018-20199-2 [PMID: 29416061].","journal-title":"Sci Rep"},{"key":"9121_CR39","doi-asserted-by":"publisher","first-page":"7129","DOI":"10.2147\/OTT.S217935","volume":"12","author":"Y Shen","year":"2019","unstructured":"Shen Y, Wang H, Chen X, Li W, Chen J. Prognostic significance of lymphocyte-to-monocyte ratio and platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma undergoing transcatheter arterial chemoembolization and radiofrequency ablation. Onco Targets Ther. 2019;12:7129\u201337. https:\/\/doi.org\/10.2147\/OTT.S217935.","journal-title":"Onco Targets Ther"},{"key":"9121_CR40","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.cmi.2016.07.019","volume":"22","author":"T Vescovo","year":"2016","unstructured":"Vescovo T, Refolo G, Vitagliano G, Fimia GM, Piacentini M. Molecular mechanisms of hepatitis C virus-induced hepatocellular carcinoma. Clin Microbiol Infect. 2016;22:853\u201361. https:\/\/doi.org\/10.1016\/j.cmi.2016.07.019.","journal-title":"Clin Microbiol Infect"},{"key":"9121_CR41","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1096\/fj.06-7345com","volume":"21","author":"Y Li","year":"2007","unstructured":"Li Y, Boehning DF, Qian T, Popov VL, Weinman SA. Hepatitis C virus core protein increases mitochondrial ROS production by stimulation of Ca2+ uniporter activity. FASEB J. 2007;21:2474\u201385. https:\/\/doi.org\/10.1096\/fj.06-7345com.","journal-title":"FASEB J"},{"key":"9121_CR42","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.molcel.2012.07.032","volume":"48","author":"GY Yu","year":"2012","unstructured":"Yu GY, He G, Li CY, Tang M, Grivennikov S, Tsai WT, et al. Hepatic expression of HCV RNA-dependent RNA polymerase triggers innate immune signaling and cytokine production. Mol Cell. 2012;48:313\u201321. https:\/\/doi.org\/10.1016\/j.molcel.2012.07.032.","journal-title":"Mol Cell"},{"key":"9121_CR43","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1002\/lt.20140","volume":"10","author":"K Shetty","year":"2004","unstructured":"Shetty K, Timmins K, Brensinger C, Furth EE, Rattan S, Sun W, et al. Liver transplantation for hepatocellular carcinoma validation of present selection criteria in predicting outcome. Liver Transpl. 2004;10:911\u20138. https:\/\/doi.org\/10.1002\/lt.20140 PMID: 15237377.","journal-title":"Liver Transpl"},{"key":"9121_CR44","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1001\/archsurg.2010.295","volume":"146","author":"B Mailey","year":"2011","unstructured":"Mailey B, Artinyan A, Khalili J, Denitz J, Sanchez-Luege N, Sun CL, et al. Evaluation of absolute serum \u03b1-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg. 2011;146:26\u201333. https:\/\/doi.org\/10.1001\/archsurg.2010.295 PMID: 21242442.","journal-title":"Arch Surg"},{"key":"9121_CR45","doi-asserted-by":"publisher","first-page":"E72","DOI":"10.1111\/ctr.12056","volume":"27","author":"LL Wong","year":"2013","unstructured":"Wong LL, Naugler WE, Schwartz J, Scott DL, Bhattacharya R, Reyes J, et al. Impact of locoregional therapy and alphafetoprotein on outcomes in transplantation for liver cancer: a UNOS region 6 pooled analysis. Clin Transpl. 2013;27:E72\u20139. https:\/\/doi.org\/10.1111\/ctr.12056 PMID: 23278701.","journal-title":"Clin Transpl"},{"key":"9121_CR46","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1111\/liv.13166","volume":"36","author":"W He","year":"2016","unstructured":"He W, Li B, Zheng Y, Zou R, Shen J, Cheng D, et al. Resection vs. ablation for alpha-fetoprotein positive hepatocellular carcinoma within the Milan criteria: a propensity score analysis. Liver Int. 2016;36:1677\u201387. https:\/\/doi.org\/10.1111\/liv.13166.","journal-title":"Liver Int"},{"issue":"16 Pt 1","key":"9121_CR47","first-page":"5902","volume":"9","author":"LH Butterfield","year":"2003","unstructured":"Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, et al. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003;9(16 Pt 1):5902\u20138 [PMID: 14676113].","journal-title":"Clin Cancer Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-021-09121-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-021-09121-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,28]],"date-time":"2022-02-28T16:07:04Z","timestamp":1646064424000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-021-09121-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,28]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["9121"],"URL":"https:\/\/doi.org\/10.1186\/s12885-021-09121-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,28]]},"assertion":[{"value":"15 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board at Mayo Clinic Rochester USA. Informed consent was waived by the same committee due to the minimal risk nature of the study, which involved only chart review with no patient contact. All study subjects have approved Minnesota Research Authorization which has given us the permission to use their data for research purposes (written consent).All study related activities were performed in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Roberts has served on advisory boards for AstraZeneca, Bayer, Eisai, Exact Sciences, Gilead Sciences, GRAIL, QED Therapeutics, and TAVEC and received research support from Ariad Pharmaceuticals, Bayer, Boston Scientific, Gilead Sciences, Glycotest, RedHill BioPharma, TARGET PharmaSolutions, and Fujifilm Medical Systems.All other authors have no competing\/conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"221"}}